<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708939</url>
  </required_header>
  <id_info>
    <org_study_id>170-2</org_study_id>
    <nct_id>NCT03708939</nct_id>
  </id_info>
  <brief_title>Microbiome and Non-caloric Sweeteners in Humans</brief_title>
  <official_title>The Role of the Microbiome in Personalized Human Response to Non-caloric Sweeteners</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weizmann Institute of Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-caloric sweeteners are common food supplements consumed by millions worldwide as means of
      combating weight gain and diabetes, by retaining sweet taste without increasing caloric
      intake. While they are considered safe, there is increasing debate regarding their potential
      role in contributing to metabolic derangements in some humans. The investigators recently
      demonstrated that non-caloric sweeteners consumption could induce glucose intolerance in mice
      and, in preliminary experiments, in distinct human subsets, by functionally altering the gut
      microbiome, and that the gut microbiome plays an important role in mediating differential
      glucose responses to identical foods. The proportion of the human population that is
      susceptible to glucose intolerance induced by non-caloric sweeteners, the common factors that
      are shared between these individuals and whether and how the microbiome promotes the
      metabolic derangements remain to be addressed.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 19, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>28 days</time_frame>
    <description>Continuous glucose monitor device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome</measure>
    <time_frame>28 days</time_frame>
    <description>Stool and oral samples</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Glucose, Low Blood</condition>
  <condition>Glucose, High Blood</condition>
  <arm_group>
    <arm_group_label>glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspartame</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sucralose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saccharin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stevia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No supplement control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Daily consumption of 5g of glucose, for 14 days.</description>
    <arm_group_label>glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aspartame</intervention_name>
    <description>Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>aspartame</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose</intervention_name>
    <description>Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>sucralose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharin</intervention_name>
    <description>Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>saccharin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Stevia</intervention_name>
    <description>Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.</description>
    <arm_group_label>Stevia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Supplement</intervention_name>
    <description>Follow up without any dietary supplementation.</description>
    <arm_group_label>No supplement control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. BMI&lt;28

          2. Age - 18-70

          3. Capable of working with smartphone application

          4. Capable to work with a glucometer

        Exclusion Criteria:

          1. Consumption of antibitioics 3 months prior to the first day of the experiment.

          2. Consumption of Non caloric sweetners 6 months prior to the first day of the
             experiment.

          3. Diagnosis with type 1 or type 2 diabetes.

          4. Pregnancy, fertility treatments

          5. Breastfeeding (Including baby to breast and bottle feeding expressed breast milk)

          6. Chronic disease (e.g. AIDS, Cushing syndrome, CKD, acromegaly, hyperthyroidism etc.)

          7. Cancer and recent anticancer treatment

          8. Psychiatric disorders

          9. Coagulation disorders

         10. IBD (inflammatory bowel diseases)

         11. Bariatric surgery

         12. Alcohol or substance abuse

         13. BMI&gt;28

         14. Aspartame group only: phenylketonuria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Elinav</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weizmann Institute of Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weizmann Institute of Science</name>
      <address>
        <city>Reáº–ovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weizmann Institute of Science</investigator_affiliation>
    <investigator_full_name>Eran Elinav</investigator_full_name>
    <investigator_title>Prof. Eran Elinav</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

